Single agent -- trastuzumab -- remains the gold standard in HER2 breast cancer care, study shows

Lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report following the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer.